Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Descartes-11 · 1 trial · 1 indication
Per IMWG 2016 Response Criteria Summary sCR: Complete response (CR) plus a normal free light chain ratio and no clonal cells in bone marrow (by immunohistochemistry). The FLC ratio must be Kappa/Lambda ≤ 4:1 or ≥ 1:2 after counting at least 100 plasma cells. CR: Negative immunofixation in serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum M-protein detectable by immunofixation (not on electrophoresis) or a ≥ 90% reduction in M-protein, with urine M-protein \<100 mg/24 hours. PR: ≥ 50% reduction in serum M-protein and a ≥ 90% reduction in 24-hour urinary M-protein (or to \<200 mg/24 hours). If M-protein is unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required. If both M-protein and serum-free light chains are unmeasurable, a ≥ 50% reduction in plasma cells is necessary, provided baseline plasma-cell percentage in bone marrow was ≥ 30%. Overall Response (OR): CR+VGPR+PR
| Arm | Type | Description |
|---|---|---|
| Descartes 11 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Descartes 11 | BIOLOGICAL | Car T-cells |
Inclusion Criteria: * Patients must be 18 years of age or older at the time of enrollment * High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs). Exclusion Criteria: * Patients who are pregnant or lactating. * Patient...
Top 20 of 25 competitors
Descartes-11 is an investigational biologic being studied for high-risk multiple myeloma. Specifically, it is being evaluated as consolidation treatment in patients who have residual disease after induction therapy. It is in Phase 2 clinical development and is not approved for any use.
Descartes-11 is being developed by Cartesian Therapeutics, Inc., which trades under the ticker RNAC. The company is advancing the asset in oncology, with multiple myeloma as its lead indication for this program.
Descartes-11 is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. Its clinical program in high-risk multiple myeloma consists of one completed Phase 2 trial.
Descartes-11 has been studied in one Phase 2 trial, NCT04436029, titled Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. The trial was conducted in the United States, enrolled 5 patients, and is now completed.
Yes, Descartes-11 and Descartes 11 refer to the same investigational therapy. The hyphenated form Descartes-11 is the standard spelling used by Cartesian Therapeutics, while Descartes 11 is a common alternate rendering used in searches and references to the same multiple myeloma program.
The Phase 2 trial NCT04436029 was an uncontrolled, open-label study without randomization or blinding. It enrolled 5 patients aged 18 years and older of all sexes, all with high-risk multiple myeloma and residual disease following induction therapy, and it did not use biomarker-based patient selection.